ClinicalTrials.gg
RecruitingNCT07348640Updated Oct 7, 2026

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

A Phase 3 interventional study of gadopiclenol and Gadoterate meglumine (Dotarem) in Steno-occlusive Disease, sponsored by Guerbet. Recruiting at 43 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 7, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Compare the diagnostic performance of gadopiclenol against gadoterate meglumine in patients with vascular diseases of supra-aortic, peripheral, or abdominal / renal arteries using MRI

Read the detailed description

To prospectively compare the diagnostic performance of gadopiclenol with gadoterate meglumine given at a dose of 0.1 mmol/kg in the diagnosis and evaluation of vascular diseases of supra-aortic (carotid/vertebrobasilar), peripheral or abdominal/renal arteries using commercial MRI scanners and MRA sequences.

02

Conditions studied

  • Steno-occlusive Disease

Keywords

  • steno-occlusive disease
  • gadopiclenol
  • Magnetic Resonnance Angiography
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 18 years of age or older willing to participate in the trial and follow all study procedures specified in the protocol.
  2. Patient having read the information in the ICF and having provided his/her consent to participate in writing by dating and signing the ICF prior to any trial related procedure being conducted.
  3. Patient with suspected steno-occlusive disease in supra-aortic (carotid/vertebrobasilar) (a), peripheral (b) or abdominal/renal (c) arteries based on:

    1. clinical signs and symptoms including but not limited to prior stroke, (TIA), amaurosis fugax (transient monocular blindness) and/or previous diagnostic tests (CTA, IA-DSA, or ultrasound) or
    2. symptoms of lower-extremity arterial disease (stages II-IV according to the Leriche-Fontaine classification, or 1 to 6 according to Rutherford classification 113 and/or confirmed by previous imaging (Doppler ultrasound, CTA, MRA, IADSA) or
    3. suspected renovascular hypertension based on one or more of the following criteria:

    i. hypertension to standard therapy ii. acute worsening of pre-existing hypertension iii. abrupt onset of sustained, moderate to severe hypertension at age \<35 years suggestive of fibromuscular dysplasia (FMD) iv. progressive renal insufficiency (creatinine > 2 mg/dL; no other apparent cause of progressive renal failure based on routine medical history, physical examination, 24-h urine collection and urinary protein excretion) v. abnormal/inconclusive renal doppler ultrasound. vi. other criteria (to be specified)

  4. Are scheduled for or had undergone CTA and/or IA-DSA according to imaging standards to cover the supra-aortic (carotid/vertebrobasilar) and/or peripheral and/or abdominal/renal territory described in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Is a pregnant or lactating female. Exclude the possibility of pregnancy for women of :

    • by testing on site at the institution (serum βHCG or urine)
    • by surgical history (e.g., tubal ligation or hysterectomy)
    • with a minimum 1 year without menses.
  2. Has any known allergy to one or more of the ingredients in the products or has a history of to other GBCAs.
  3. Has severe renal impairment defined as an estimated (eGFR) below 30 mL/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) formula.
  4. Has known or suspected acute kidney injury (AKI) based on: a. Increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 hours or b. Increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within prior 7 days or c. Urine volume \< 0.5 mL/kg/h for 6 hours
  5. Has received any contrast agent (for MRI, CT, DSA) prior to the first IMP administration or is scheduled to receive any contrast agent between the two MRA or after the second IMP administration.
  6. Has received or is scheduled for therapeutic intervention (e.g., endovascular therapy, vascular surgery, etc.) of any kind for vascular disease in the arterial territory of interest performed between the 2 MRA procedures or between the study MRAs and the CTA/IADSA procedures when applicable.
  7. Has any to MRI.
  8. Is suffering from severe claustrophobia.
  9. Has received an investigational drug or medical device before admission into this study or scheduled to receive any investigational treatment in the course of the trial.
  10. Was previously included in this trial.
  11. Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
315 participants (estimated)

Study arms

  • Experimental
    AB

    Gadopiclenol administered first followed by Gadoterate meglumine 0.1 mmol/kg

    Drug: gadopiclenol · Drug: Gadoterate meglumine (Dotarem)

  • Active comparator
    BA

    Gadoterate meglumine 0.1 mmol/kg administered first followed by Gadopiclenol

    Drug: gadopiclenol · Drug: Gadoterate meglumine (Dotarem)

Interventions

06

What researchers measure

Primary outcomes

  1. Non-inferiority

    To demonstrate the non-inferiority of gadopiclenol-enhanced Magnetic Resonance Angiography (MRA) compared to gadoterate meglumine enhanced MRA at 0.1 mmol/kg body weight in terms of sensitivity and specificity for detecting clinically significant steno-occlusive disease at segment level using Computerized Tomography Angiography (CTA) and/or Intra-arterial-Digital Subtraction Angiography (IA-DSA) findings as Standard of Truth.

    Time frame: 30 days

Secondary outcomes

  1. Adverse Events

    To assess the safety profile of gadopiclenol and gadoterate meglumine 0.1 mmol/kg in terms of incidence of adverse events and changes in vital signs.

    Time frame: 30 days

07

Study locations

17 of 43 sites recruiting
  • University of Alabama
    Birmingham, Alabama 35233, United States
    Not yet recruiting
    • Manoj Tanwar, MD · Contact
  • University of California Los Angeles (UCLA)
    Los Angeles, California 90095-7206, United States
    Not yet recruiting
    • Arash Bedayat, MD · Contact
  • UCHealth University of Colorado Hospital
    Aurora, Colorado 80045, United States
    Not yet recruiting
    • David Zander, MD · Contact
  • Northshore - Evanston Hospital
    Evanston, Illinois 60201, United States
    Recruiting
    • Robert Edelman, MD · Contact
  • Mayo Clinic
    Rochester, Minnesota 55901, United States
    Not yet recruiting
    • Jeremy Collins, MD · Contact
  • University of Washington
    Seattle, Washington 98185, United States
    Not yet recruiting
    • Majid Chalian, MD · Contact
  • Centre Hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 3J2, Canada
    Not yet recruiting
    • Gilles Soulez, MD · Contact
  • Seaman MRI research centre
    Calgary, Canada
    Not yet recruiting
    • Johanna Ospel, MD · Contact
  • Department of Radiology and Nuclear Medicine, University Hospital Brno
    Brno, 625 00, Czechia
    Not yet recruiting
    • Marek Mechl, MD · Contact
  • Motol University Hospital
    Prague, 150 06, Czechia
    Not yet recruiting
    • Lukáš Lambert Miksik, MD · Contact
  • CHU Hopitaux de Bordeaux - Groupe Hospitalier Pellegrin
    Bordeaux, 33076, France
    Recruiting
    • Thomas Tourdias, MD · Contact
  • Hôpital Cardiovasculaire et Pneumologique
    Bron, 69500, France
    Recruiting
    • Philippe Douek, MD · Contact
  • CHU Dijon Bourgogne
    Dijon, 21079, France
    Recruiting
    • Romaric Loffroy, MD · Contact
  • CHU de Poitiers
    Poitiers, 86000, France
    Not yet recruiting
    • Rémy Guillevin, MD · Contact
  • Charité - Universitätsmedizin Berlin
    Berlin, 13353, Germany
    Not yet recruiting
    • Dominik Giesel, MD · Contact
  • University Hospital Bonn
    Bonn, Germany
    Not yet recruiting
    • Alexander Isaak, MD · Contact
  • University of Bielefeld, Klinikum Lippe
    Detmold, 32756, Germany
    Not yet recruiting
    • Michel Eisenblätter, MD · Contact
  • UH Essen
    Essen, 45147, Germany
    Not yet recruiting
    • Yan Li, MD · Contact
  • University Hospital of Saarland
    Homburg, 66421, Germany
    Not yet recruiting
    • Gunter Schneider, MD · Contact
  • Klinik fuer Diagnostische Radiologie and Neuroradiologie
    Kiel, D-24105, Germany
    Recruiting
    • Sönke Peters, MD · Contact
  • Department of Neuroradiology, UKSH Campus Lübeck
    Lübeck, 23538, Germany
    Not yet recruiting
    • Peter Schramm, MD · Contact
  • Semmelweis University - Budapest
    Budapest, 1122, Hungary
    Recruiting
    • Bela Merkely, MD · Contact
  • University of Debrecen - Debrecen
    Debrecen, Hungary
    Recruiting
    • Oláh László, MD · Contact
  • University of Pecs Clinical Centre
    Pécs, 7623, Hungary
    Recruiting
    • Attila Schwarcz, MD · Contact
  • Albert Szent-Györgyi Medical Center
    Szeged, 6725, Hungary
    Not yet recruiting
    • Zsigmond Kincses, MD · Contact
  • Reparto di Neuroradiologia ASST Ospedale Papa Giovanni XXIII
    Bergamo, 34127, Italy
    Recruiting
    • Simonetta Gerevini, MD · Contact
  • Azienda Ospedaliera di Monserrato
    Cagliari, 09124, Italy
    Recruiting
    • Luca Saba, MD · Contact
  • ITAB -Institute of Advanced Biomedical Technologies University d'Annunzio of Chieti-Pescara
    Chieti, Italy
    Recruiting
    • Massimo Caulo, MD · Contact
  • Department of Diagnostic Imaging, Humanitas Research Hospital
    Milan, 20089, Italy
    Not yet recruiting
    • Andrea Laghi, MD · Contact
  • Diagnostica per Immagini e Interventistica Ospedale Umberto I
    Roma, 00161, Italy
    Recruiting
    • Carlo Catalano, MD · Contact
  • Catholic University - Fondazione Policlinico Gemelli Advanced Radiology Center - Diagnostic Imaging and Oncologic Radiotherapy Dept. IRCCS Rome
    Roma, 00168, Italy
    Recruiting
    • Luigi Natale, MD · Contact
  • Ospedale Ca' Foncello
    Treviso, 31100, Italy
    Recruiting
    • Giovanni Morana, MD · Contact
  • University Hospital No.1, Department of Radiology and Diagnostic Imagine
    Bydgoszcz, 85-094, Poland
    Not yet recruiting
    • Zbigniew Serafin, MD · Contact
  • Radiology Department, Uniwersyteckie Centrum Kliniczne w Gdansku
    Gdansk, 80-952, Poland
    Not yet recruiting
    • Katarzyna Dziadziuszko, MD · Contact
  • Medical University Lublin, Diagnostic Imaging Department
    Lublin, Poland
    Not yet recruiting
    • Radoslaw Pietura, MD · Contact
  • Yonsei University Gangnam Severance Hospital
    Seoul, Gangnam-gu 06273, South Korea
    Not yet recruiting
    • Sang Hyun Suh, MD · Contact
  • Seoul National University Hospital
    Seoul, Jongno-gu 03080, South Korea
    Not yet recruiting
    • Whal Lee, MD · Contact
  • Seoul St. Mary's Hospital
    Seoul, Seocho-gu, South Korea
    Not yet recruiting
    • Joon Yong Jung, MD · Contact
  • Asan Medical Center
    Seoul, Songpa-gu, South Korea
    Not yet recruiting
    • Ho-Sung Kim, MD · Contact
  • Ajou University Hospital
    Gyeonggi-do, Suwon-si 16499, South Korea
    Not yet recruiting
    • Jin Wook Choi, MD · Contact
  • Diagnòstic per la Imatge
    Barcelona, 08025, Spain
    Recruiting
    • Josep Munuera, MD · Contact
  • Hospital Clínico San Cecilio
    Granada, 18007, Spain
    Recruiting
    • Jose Luis Martín Rodríguez, MD · Contact
  • Hospital Nuestra, Resonancia Magnetica NTRA
    Madrid, 28006, Spain
    Recruiting
    • Eliseo Vañó Galván, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 16, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 2 sites removed. 15 sites changed recruiting status (15 now recruiting)
Show 15 sites
  • Northshore - Evanston Hospital · Evanston, United StatesNot yet recruiting→Recruiting
  • CHU Hopitaux de Bordeaux - Groupe Hospitalier Pellegrin · Bordeaux, FranceNot yet recruiting→Recruiting
  • Hôpital Cardiovasculaire et Pneumologique · Bron, FranceNot yet recruiting→Recruiting
  • CHU Dijon Bourgogne · Dijon, FranceNot yet recruiting→Recruiting
  • Klinik fuer Diagnostische Radiologie and Neuroradiologie · Kiel, GermanyNot yet recruiting→Recruiting
  • Semmelweis University - Budapest · Budapest, HungaryNot yet recruiting→Recruiting
  • Reparto di Neuroradiologia ASST Ospedale Papa Giovanni XXIII · Bergamo, ItalyNot yet recruiting→Recruiting
  • Azienda Ospedaliera di Monserrato · Cagliari, ItalyNot yet recruiting→Recruiting
  • ITAB -Institute of Advanced Biomedical Technologies University d'Annunzio of Chieti-Pescara · Chieti, ItalyNot yet recruiting→Recruiting
  • Diagnostica per Immagini e Interventistica Ospedale Umberto I · Roma, ItalyNot yet recruiting→Recruiting
  • Catholic University - Fondazione Policlinico Gemelli Advanced Radiology Center - Diagnostic Imaging and Oncologic Radiotherapy Dept. IRCCS Rome · Roma, ItalyNot yet recruiting→Recruiting
  • Ospedale Ca' Foncello · Treviso, ItalyNot yet recruiting→Recruiting
  • Diagnòstic per la Imatge · Barcelona, SpainNot yet recruiting→Recruiting
  • Hospital Clínico San Cecilio · Granada, SpainNot yet recruiting→Recruiting
  • Hospital Nuestra, Resonancia Magnetica NTRA · Madrid, SpainNot yet recruiting→Recruiting
Show 4 added (1 United States, 1 Canada, 1 Germany, 1 Hungary)
  • University of Alabama · Birmingham, United States
  • Seaman MRI research centre · Calgary, Canada
  • University of Bielefeld, Klinikum Lippe · Detmold, Germany
  • Albert Szent-Györgyi Medical Center · Szeged, Hungary
Show 2 removed
  • Houston Methodist Hospital · Houston, United States
  • LMU University Hospital · München, Germany
Oct 7, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • University of California Los Angeles (UCLA) · Los Angeles, United StatesContact •••8708→none listedContact a•••@mednet.ucla.edu→none listed
  • UCHealth University of Colorado Hospital · Aurora, United StatesContact •••1597→none listedContact d•••@cuanschutz.edu→none listed
  • Northshore - Evanston Hospital · Evanston, United StatesContact •••2098→none listedContact R•••@northshore.org→none listed
  • Mayo Clinic · Rochester, United StatesContact •••1681→none listedContact C•••@mayo.edu→none listed
  • University of Washington · Seattle, United StatesContact •••6868→none listedContact m•••@uw.edu→none listed
  • UH Essen · Essen, GermanyContact person changed (no phone or email listed)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    4 sites added, 2 sites removed. 15 sites changed recruiting status (15 now recruiting)
    Show 15 sites
    • Northshore - Evanston Hospital · Evanston, United StatesNot yet recruiting→Recruiting
    • CHU Hopitaux de Bordeaux - Groupe Hospitalier Pellegrin · Bordeaux, FranceNot yet recruiting→Recruiting
    • Hôpital Cardiovasculaire et Pneumologique · Bron, FranceNot yet recruiting→Recruiting
    • CHU Dijon Bourgogne · Dijon, FranceNot yet recruiting→Recruiting
    • Klinik fuer Diagnostische Radiologie and Neuroradiologie · Kiel, GermanyNot yet recruiting→Recruiting
    • Semmelweis University - Budapest · Budapest, HungaryNot yet recruiting→Recruiting
    • Reparto di Neuroradiologia ASST Ospedale Papa Giovanni XXIII · Bergamo, ItalyNot yet recruiting→Recruiting
    • Azienda Ospedaliera di Monserrato · Cagliari, ItalyNot yet recruiting→Recruiting
    • ITAB -Institute of Advanced Biomedical Technologies University d'Annunzio of Chieti-Pescara · Chieti, ItalyNot yet recruiting→Recruiting
    • Diagnostica per Immagini e Interventistica Ospedale Umberto I · Roma, ItalyNot yet recruiting→Recruiting
    • Catholic University - Fondazione Policlinico Gemelli Advanced Radiology Center - Diagnostic Imaging and Oncologic Radiotherapy Dept. IRCCS Rome · Roma, ItalyNot yet recruiting→Recruiting
    • Ospedale Ca' Foncello · Treviso, ItalyNot yet recruiting→Recruiting
    • Diagnòstic per la Imatge · Barcelona, SpainNot yet recruiting→Recruiting
    • Hospital Clínico San Cecilio · Granada, SpainNot yet recruiting→Recruiting
    • Hospital Nuestra, Resonancia Magnetica NTRA · Madrid, SpainNot yet recruiting→Recruiting
    Show 4 added (1 United States, 1 Canada, 1 Germany, 1 Hungary)
    • University of Alabama · Birmingham, United States
    • Seaman MRI research centre · Calgary, Canada
    • University of Bielefeld, Klinikum Lippe · Detmold, Germany
    • Albert Szent-Györgyi Medical Center · Szeged, Hungary
    Show 2 removed
    • Houston Methodist Hospital · Houston, United States
    • LMU University Hospital · München, Germany
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • University of California Los Angeles (UCLA) · Los Angeles, United StatesContact •••8708→none listedContact a•••@mednet.ucla.edu→none listed
    • UCHealth University of Colorado Hospital · Aurora, United StatesContact •••1597→none listedContact d•••@cuanschutz.edu→none listed
    • Northshore - Evanston Hospital · Evanston, United StatesContact •••2098→none listedContact R•••@northshore.org→none listed
    • Mayo Clinic · Rochester, United StatesContact •••1681→none listedContact C•••@mayo.edu→none listed
    • University of Washington · Seattle, United StatesContact •••6868→none listedContact m•••@uw.edu→none listed
    • UH Essen · Essen, GermanyContact person changed (no phone or email listed)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07348640
Lead sponsor
Guerbet
Collaborators
Bracco Imaging S.p.A.
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jul 28, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Sophie Rollin, PhD
Contact
sophie.rollin@guerbet.com
+33688196716
Frantz Hébert, MSc
Contact
frantz.hebert@guerbet.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gadopiclenol · Gadoterate meglumine

Start the discussion